AbbVie ( (ABBV) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
AbbVie’s stock surged as the company unveiled its Q4 2024 earnings, surpassing Wall Street’s expectations. The company reported adjusted earnings per share of $2.16 and revenue of $15.102 billion, driven by growth in immunology, oncology, and neuroscience. Despite a drop in aesthetics revenue, strong earnings and a promising 2025 outlook, particularly for Skyrizi and Rinvoq, bolstered investor confidence. Analysts are considering updates to ratings and price targets following this impressive performance.
More about AbbVie
YTD Price Performance: -0.22%
Average Trading Volume: 6,480,626
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $310.4B
For further insights into ABBV stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.